ARBORXR
7.10.2021 16:55:09 CEST | Business Wire | Press release
ArborXR , the leading enterprise AR/VR device management and content distribution platform, and AR/VR solutions distributor, Matts Digital , today announced a partnership to provide frictionless extended reality (XR) solutions at scale in Europe and beyond. With ArborXR’s mobile device management (MDM) software, Matts Digital will help companies securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset user experience. The partnership illustrates an accelerated shift to remote work and training amid the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005755/en/
According to Forbes , global spending on AR/VR rose to $12 billion in 2020, up 50 percent from 2019.
“ArborXR and Matts Digital share a mission to help companies use and scale XR technology with ease, while offering exceptional customer service,” said ArborXR Co-Founder Will Stackable. “By partnering with Matts Digital, ArborXR is able to help global enterprise companies succeed and increase efficiency through the power of XR. We’re thrilled to enter the European market and provide vital software to help companies deploy AR/VR with confidence.”
Matts Digital offers an extensive range of AR/VR products, in addition to unique XR technology professional services. By utilizing ArborXR’s software, Matts Digital will help companies manage thousands of devices with security and control.
“Matts Digital is pleased to work with ArborXR to offer best-in-class XR solutions for a variety of global companies. Together, we will help customers use XR devices with confidence and achieve our shared goal to increase the simplicity, security and efficiency of XR in the workplace,” Matts Digital President Stephane Courgeon said.
To learn more about ArborXR or Matts Digital, visit ArborXR.com or Matts-Digital.com .
About ArborXR
ArborXR is AR/VR mobile device management (MDM) software that allows enterprise companies to securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset experience. It is used by Fortune 500 companies, businesses, and hundreds of independent software vendors to seamlessly manage devices, enroll and provision headsets, deploy apps and files remotely, and lock down the user experience with kiosk mode and a multi-app launcher. Learn more about ArborXR and its recent completion of a Series A at ArborXR.com .
About Matts Digital
Matts Digital is a Value-Added distributor, specializing in Virtual Reality (VR) and Augmented Reality (AR) solutions. We offer a full range of headsets, peripherals, accessories and hygiene products, as well as unique professional services in this area. Our significant industrial and logistical capacity allows our customers to easily consider the deployment of their ARVR projects on a large scale, in France and abroad. Learn more at Matts-Digital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005755/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom